This Stock Has Almost Tripled in 6 Months. Here's What Investors Need to Watch Next

Tilray shares have risen nearly 200% over the past six months amid expectations that President Trump’s executive order reclassifying marijuana from Schedule I to Schedule III will pass, a change that would ease medical research, improve banking access and eliminate the punitive tax treatment that prevents normal business deductions. However, Tilray currently derives no U.S. cannabis sales (only hemp and a large craft-brewing business), remains unprofitable in most quarters, and would face federal interstate transport limits and intense incumbent competition if it expands, making a clear upside for Tilray uncertain. Given weak recent financials and competitive risks despite favorable regulatory shifts, the article concludes investors should avoid the stock.

Analysis

Market structure: Re‑scheduling to Schedule 3 structurally benefits US multi‑state operators (MSOs), payment processors and cannabis‑adjacent suppliers by reducing tax and banking frictions; expect a 10–30% boost to EBITDA margins industry‑wide over 12–24 months if IRS/Treasury issues guidance removing 280E applicability. Tilray (TLRY) is a second‑order beneficiary — it has near‑zero US cannabis revenue today and a 200% rally priced in speculative entry; market share gains will be contested by entrenched US MSOs (Curaleaf, Green Thumb, Trulieve).

Risk assessment: Tail risks include reversal by courts or future administrations, delayed/partial IRS guidance (6–12+ months), and a U.S. oversupply cycle similar to Canada that can depress prices 20–50% within 12–36 months. Near term (days–weeks) volatility should remain high on headlines; short‑medium term (3–9 months) depends on Treasury/IRS memos and bank underwriting updates; long term (1–3 years) hinges on interstate transport rules and consolidation/M&A.

Trade implications: Favor selective long exposure to established US MSOs (CURLF, GTBIF, TCNNF) and payments/ancillary names; avoid momentum longs in TLRY until demonstrable US revenue or accretive M&A. Use option skew: buy 3–9 month put spreads on TLRY and buy 6–12 month OTM calls on high‑quality MSOs to play normalization of tax/banking; consider pair trades (long MSO, short TLRY) to neutralize sector beta.

Contrarian angles: Consensus assumes rescheduling equals immediate commercial access — that’s overstated. Banking and 280E relief require administrative guidance and bank de‑risking (3–12 months); market is likely overpricing TLRY’s U.S. optionality today. If IRS guidance is slow or states maintain restrictive rules, expect a rapid re‑rating of speculative names and a flight to scale leaders.

Key Decisions for Investors

• Establish a 2–3% portfolio long basket in proven US MSOs (equal weight CURLF, GTBIF, TCNNF) with a 6–12 month horizon; target 25–50% upside if tax/banking relief materializes, set trailing stop‑loss at 20% to protect against oversupply drawdowns.
• Initiate a tactical 2% short position in TLRY (or buy 3–6 month ATM put spread 1x2) to exploit the 200% run‑up that lacks current US revenue; cover or reassess after any announced US cannabis revenue stream or if TLRY falls >40% from current levels (take profit).
• Implement a pair trade: long 6–12 month call spreads on top MSO (e.g., GTBIF) and short 6–12 month call spreads on TLRY to capture asymmetric upside in operators vs. speculative integrators; size to be dollar‑neutral and re‑weight after IRS/Treasury guidance.
• Avoid adding to Canadian pure‑play cannabis growers without clear U.S. distribution paths; reduce exposure to highly levered cannabis equities by 50% within 30 days pending IRS guidance and bank adoption signals (look for >3 regional banks announcing cannabis servicing within 90 days).
• Monitor three binary catalysts over the next 90–180 days before scaling: (1) Treasury/IRS guidance on 280E (target: explicit promulgation within 90–180 days), (2) major US banks publishing underwriting criteria for cannabis clients, and (3) TLRY announcing US M&A or organic cannabis launch — act only if at least two occur.